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ABSTRACT: The incidences of obesity and type 2 diabetes
are rapidly increasing and have evolved into a global epidemic.
In this study, we analyzed the molecular effects of high-fat diet
(HFD)-induced insulin-resistance on mice in two metabolic
target tissues, the white adipose tissue (WAT) and the liver.
Additionally, we analyzed the effects of drug treatment using
the specific PPARγ ligand rosiglitazone. We integrated
transcriptome, proteome, and metabolome data sets for a
combined holistic view of molecular mechanisms in type 2
diabetes. Using network and pathway analyses, we identified
hub proteins such as SDHB and SUCLG1 in WAT and
deregulation of major metabolic pathways in the insulin-
resistant state, including the TCA cycle, oxidative phosphorylation, and branched chain amino acid metabolism. Rosiglitazone
treatment resulted mainly in modulation via PPAR signaling and oxidative phosphorylation in WAT only. Interestingly, in HFD
liver, we could observe a decrease of proteins involved in vitamin B metabolism such as PDXDC1 and DHFR and the according
metabolites. Furthermore, we could identify sphingosine (Sph) and sphingosine 1-phosphate (SP1) as a drug-specific marker pair
in the liver. In summary, our data indicate physiological plasticity gained by interconnected molecular pathways to counteract
metabolic dysregulation due to high calorie intake and drug treatment.
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■ INTRODUCTION
Metabolic disorders such as obesity and type 2 diabetes are a
major current health problem, in particular in countries of
growing economic power, along with significant lifestyle
changes such as low physical activity and high-calorie intake.1
Researchers have been extensively studying the etiology and
molecular mechanisms of these disorders to gain basic insights
and develop treatment strategies. However, physiological
alterations resulting from environmental changes such as high
calorie intake do not affect only a few key proteins or other
functionally important biomolecules. Instead, homeostasis is
secured by the robustness of molecular networks.2,3 It is thus
conceivable that identification of deregulated pathways and
networks is a fruitful discovery approach, as a starting point for
later analyses of molecular mechanisms and validation of
potential disease biomarkers.
The initial proteomic-based studies in the diabetes research
field have included proteomic studies of pancreatic islets in
animal models of obesity and diabetes,4 diabetic nephropathy,5
pancreas from pancreatectomy models,6 fat,7 muscle,8 and
liver.9,10 Results of such studies were usually limited to short
lists of regulated proteins.
Furthermore, recent metabolite studies in blood, plasma, or
serum indicated potential physiological deregulation in diabetic
mice and patients.11,12 Recently, combined RNA expression
and metabolite analyses were shown for diabetic mouse
models,13 but these studies could not systematically decipher
potential impact of the most functionally relevant proteins.
Recently, we started analyses in various diabetic mouse
models,14,15 introducing the concept of protein sets for
providing diagnostic tools for preclinical drug development.16
In this study, we primarily aimed to gain a holistic view on the
physiological deregulation in a high-fat diet (HFD)-induced
insulin-resistance mouse model. Therefore, we used compre-
hensive data sets of transcripts, proteins, and metabolites
derived from two major metabolic target tissues, the white
adipose tissue (WAT) and the liver. We further aimed to
analyze the effects of the diabetes drug rosiglitazone (RGZ), a
thiazolidinedione which specifically targets the peroxisome
proliferator-activated receptor gamma (PPARγ).17 The nuclear
receptor PPARγ is highly abundant in WAT, suggesting that the
insulin-sensitizing effects of RGZ are mainly driven by
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physiological effects derived from fat tissue,18 whereas PPARγ is
less abundant in liver.
Therefore, we analyzed WAT and liver tissue on a global
scale in terms of (i) the relative expression levels of coding
transcripts based on microarray analyses, (ii) the relative
expression levels of proteins based on shotgun LC-MS/MS
using a SILAC mouse approach with 13C6-lysine-labeled
reference tissues, and (iii) the relative metabolite abundances
based on targeted LC-MS/MS technology. All data were
derived from the same mouse cohorts.
■ EXPERIMENTAL PROCEDURES
Mouse Samples
Animal studies were carried out according to internationally
approved standards, as described recently,15,16 and have been
validated and approved by the State Office of Health and Social
Affairs, Berlin (LAGeSo). As stated previously “the animals
were maintained one per cage under temperature-, humidity-,
and light-controlled conditions (22°C, 50% humidity, 12 h
light/12 h dark cycle). The health status and behaviour of mice
were examined daily. Mice had ad libitum access to food and
water. Mice and food were weighed regularly to determine
changes in body weight and food intake. Low-fat diet (LFD,
D12450B, 10 kcal% fat, 18.0 MJ/kg, ssniff, Soest, Germany)
was composed of the following: 4.1% crude fat, 18.1% crude
protein, 26.6% starch, 35.5% sugar/dextrines, 4.7% crude fiber.
High-fat diet (HFD, D12492, 60 kcal% fat, 25.3 MJ/kg, ssniff)
was composed of the following: 34.0% crude fat, 24.1% crude
protein, 1.1% starch, 23.8% sugar/dextrines, 6.0% crude fiber.16
Six-week-old male C57BL/6 mice were fed a high-fat diet
(HFD) for 12 weeks to generate insulin-resistant diet-induced
obesity (DIO) mice. Then, the mice were weighed and equally
distributed to two groups (n = 13 each). DIO mice were treated
over 3 weeks with 4 mg/kg/d RGZ or vehicle only. Mice of
similar age fed with low-fat diet (LFD) were considered as
healthy controls. Liver and visceral white adipose tissue were
dissected, washed in phosphate-buffered saline (PBS, pH7.4),
and shock frozen in liquid nitrogen. Plasma and tissues were
stored at −80 °C before use.
To document HFD-induced insulin resistance and the
physiological effects of RGZ treatment in all mice, we
determined the fasted levels of glucose, insulin, triglycerides,
and free fatty acids in plasma, using standard procedures.14
Homeostasis model assessment of insulin resistance (HOMA-
IR) was determined as follows: fasting glucose (mg/dL) ×
fasting insulin (μU/mL)/405.19
Gene Expression Analysis
Genome-wide RNA expression analysis was done using
standard procedures including Illumina sample preparation
protocols and the Illumina BeadStation 500 platform as
described recently.16 Integrity of RNA was checked by use of
standard agarose gel electrophoresis and ethidium bromide
staining. Samples from randomly chosen mice of a treatment
cohort were analyzed using at least biological triplicates. Basic
expression data analyses were performed using GenomeStudio
V2011.1 (Illumina). Raw data were background-subtracted and
normalized applying the cubic spline algorithm. Processed data
were subsequently filtered for significant detection (P value
≤0.01) and differential expression vs vehicle treatment
according to the Illumina t test error model, and were
corrected according to the Benjamini−Hochberg method (P
value ≤0.05) of the GenomeStudio software. Gene expression
data were submitted in MIAME-compliant form to the NCBI
Gene Expression Omnibus database (GSE38856). All double
log blots were made in Perseus v.1.4.0.8.20 For consistency, all
gene and protein information was retrieved from the
UniProtKB (www.uniprot.org, April 2014).
Protein Expression Analysis
Protein data analysis was based on a previous study published
by us.16 In brief, to cope with large variability of protein
expression comparted to RNA expression in animal tissues,
pools from eight randomly chosen mice per cohort were
sampled in frozen condition, as described recently.16 A lysis
buffer containing 4% SDS, 0.1 M DTT, 0.1 M Tris pH 8.0 was
added. SILAC mouse reference tissues (13C6-lysine-labeled
reference tissues (Silantes, Martinsried, Germany)) were lysed
in the same way. For protein separation, samples were mixed
1:1 with the SILAC reference samples. About 200 μg of protein
was loaded onto a 12% SDS gel, and 18 fractions were Lys-C
digested. Each sample was dissolved in 5% ACN, 2% FA and
were used for LC-MS analysis.
Nano liquid chromatography (LC), online coupled to a
Linear Ion Trap (LTQ)-Orbitrap XL mass spectrometer
(Thermo-Electron Corp) was used to sequence peptides
eluting from a PicoFrit analytical column (75 μm ID × 150
mm long, 15 μm Tip ID (New Objectives, Woburn, MA)) in-
house packed with 3 μm C18 resin (Reprosil-AQ Pur, Dr.
Maisch, Germany). A nonlinear gradient from 2 to 40% solvent
B over 160 min at a flow rate of 200 nL/min (solvent A: 97.9%
H2O, 2% acetonitrile, 0.1% formic acid; solvent B: 97.9%
acetonitrile, 2% H2O, 0.1% formic acid) was used. A voltage of
1.8 kV was applied for nanoelectrospray generation. A cycle of
one full FT scan mass spectrum (300−2000 m/z, resolution of
60 000 at m/z 400) was followed by 10 data-dependent MS/
MS scans acquired in the linear ion trap with normalized
collision energy (setting at 35%). Target ions already selected
for MS/MS were dynamically excluded for 60 s. Raw files for
each LC−MS/MS experiment were submitted to MaxQuant
v1.0.13.13 for data processing. The cutoff value was set to 1%
FDR. As SILAC modification, we used 13C6-labeled lysine. The
following chemical modifications were selected as variable
modifications: protein N-terminal acetylation and methionine
oxidation. Carbamidomethyl C was used as fixed modification.
Lys-C was set with a maximum of two missed cleavage sites.
Mass tolerance for precursor and fragment ions was 0.5 Da and
7 ppm. Sample pools were run as technical replicates,
respectively. Raw- and MaxQuant processed mass spectrometry
data that were used in this study can be downloaded via: ftp://
PASS00201:BG7335ub@ftp.peptideatlas.org/.
As desribed recently,16 protein expression changes between
samples were calculated using the formula below:
Metabolite Extraction
Metabolite analysis was done with the same tissue samples as
for protein expression analysis (see above). Tissues were
dissected, washed in phosphate-buffered saline (PBS, pH7.4),
and shock frozen in liquid nitrogen. To enable discovery of
reliable changes in metabolome states in visceral adipose and
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liver tissue, we used pools from eight randomly chosen mice
(100−160 mg in total) per treatment cohort. The final ratio of
solvents used in the biphasic methanol/chloroform/water
extraction method was 2.0/2.0/1.8.21 Cold methanol (500
μL, −20 °C) and 107 μL of water were added to the frozen
tissue pools and subsequently homogenized by FastPrep
(settings: 2 × 40 s; 4.5 m/s) with a steel ball. Samples were
kept on ice, and 250 μL of chloroform was added to the
homogenate. Appropriate safety guidelines have to be put in
place while working with chloroform. Samples were vortexed
for 10 min and centrifuged for 5 min at 2000g at 4 °C to
remove debris and precipitated protein. The supernatant was
transferred to a new tube, and 250 μL of chloroform and 250
μL of water were added. Samples were again vortexed for 60 s,
kept on ice for 10 min for phase separation, and centrifuged for
10 min at 2000g at 4 °C. Resulting upper polar and lower
nonpolar fractions were separately transferred and combined in
three clean tubes containing the internal standard chloramphe-
nicol, dedicated for subsequent analysis by using methanol,
acetonitrile, and water as alternative solvents for LC-MS runs.
Samples were lyophilized in the centrifugal concentrator.
Targeted LC-MS/MS Analysis of Metabolites
We applied a multi reaction monitoring (MRM)-based strategy
to identify differences in metabolite abundance of sample
cohorts. The residuals from the previous step were suspended
in 35 μL of acetonitrile, 0.1% formic acid and 35 μL of
methanol, 0.1% formic acid for analysis by HILIC mode and in
20 μL of water, 0.1% formic acid for RPLC mode. Samples
were centrifuged at 17 500g for 5 min at 4 °C. Samples were
further cleaned to avoid column clogging (iso-disc filters PTFE
13 mm × 0.2 mm, Supelco, Bellafonte, PA). The supernatants
were transferred to microvolume inserts, and 5 μL per run was
injected for LC-MS/MS analysis. The sample pools were run as
technical triplicates.
Metabolites were analyzed using an online coupled LC-MS/
MS system (1290 Infinity UHPLC, Agilent, Santa Clara, CA;
QTrap 6500, ABSciex, Toronto, Canada) featuring a Reprosil-
PUR C18-AQ (1.9 μm, 120 Å, 150 × 2 mm ID; Dr. Maisch;
Ammerbuch, Germany) column and a zicHILIC (3.5 μm, 100
Å, 150 × 2.1 mm ID; di2chrom; Marl, Germany) column at
controlled temperature of 30 °C. The chromatographic
separations were performed on RP and zicHILIC stationary
phases. The UHPLC was run with four different buffer
conditions: A1:10 mM ammonium acetate in LC-MS grade
water (adjusted with formic acid to pH 3.5); A2:10 mM
ammonium acetate in LC-MS grade water (adjusted with
ammonium hydroxide to pH 7.5); B1: LC-MS grade
acetonitrile; 0.1% FA; B2: LC-MS grade methanol; 0.1%
formic acid. Gradients and flow conditions are described in
Supporting Information, Table 1. The columns were
equilibrated with a blank run in the according buffer system,
and in the case of methanol methods, three blank runs were
necessary for a proper equilibration.
MS-Data acquisition was performed with an ion spray voltage
of 5.5 kV in positive mode and 4.5 kV in negative mode of the
ESI source. Nitrogen as collision gas was set to high, curtain gas
to 30 psi, ion source gas 1 and 2 to 50 and 70 psi, respectively,
and an interface heater temperature of 350 °C was used. The
mass spectrometer was operated with AB Sciex Analyst 1.6.1
software with components for 6500 series instruments.
Transitions were monitored and acquired at unit resolution
(peak width at 50% was 0.7 Da ± 0.1 Da tolerance) in
quadrupole Q1 and Q3. At least two transitions per metabolite
were monitored in this MRM based method. The scheduled
MRM algorithm, monitoring transitions only 300 s around the
expected retention time, was used to decrease the number of
concurrent MRMs monitored at any time point.
Metabolite MS Data Integration
Compound quantification was performed using MultiQuant
software v.2.1.1 (AB Sciex, Foster City, CA). Integration
settings were a Gaussian smooth width of 2 points and a peak
splitting factor of 2. Peak integrations were reviewed manually,
and results tables were exported as Excel files. Metabolite
identification was based on co-occurring transitions at the
expected retention time and at least 10 times smaller peak areas
in blank runs. An additional feature used to correctly identify
analytes was the ratio between the transitions, which had to
match the ratios of the according tuned pure metabolites.
Samples were normalized according to the weight of used tissue
per cohort. The average ratio from all MRMs of one metabolite
was used to calculate the log fold change between sample
cohorts. Perseus v.1.4.0.8 was used for generating density
scatter blots.
Gene/Protein Set Enrichment, Network, and Pathway
Analyses
We used the Gene Set Enrichment Analysis (GSEA) tool,22
v2.0.14 (http://www.broadinstitute.org/gsea/index.jsp) to ana-
lyze whether an a priori defined set of genes or proteins
revealed statistical significance and concordant differences
between two biological states. In general, the following
parameters were chosen if not otherwise noted: 10 000 gene/
protein set permutations, weighted enrichment statistics,
minimal gene/protein set size of 5, and log2 ratio metric
with preranking. RNA expression data and protein SILAC
ratios were analyzed using the KEGG database (version 4.0,
186 pathways) from the Molecular Signature Database
(MSigDB). We considered regulated pathways only as
statistically significant, if the FDR was ≤0.25. Heatmaps were
carried out with Mayday 2.13.23 Qualitative correlation was
determined as the part of the genes that were regulated in a
similar direction by RNA and protein expression. A correlation
of 50% was considered as random. For correlation analyses on
the single gene/protein level, genes and proteins were filtered
for candidates with fold change ≥1.33 or ≤0.75 for RNA or
protein. For correlation analyses on pathway levels, we
compared the KEGG pathway regulation determined by
GSEA, and we included only regulated pathways with FDR ≤
0.25 for RNA or protein. Correlation analyses were done
separately for each treatment and tissue.
To identify the main hub proteins, we generated interaction
networks using STRING 9.1.24 We applyed a high confidence
score of 0.7, which implies that only interactions with a high
level of confidence were extracted from the database and
considered as valid links for protein−protein interaction (PPI)
networks.
Interaction networks were extracted and further analyzed and
evaluated using the Cytoscape v3.1.125 plugin called “network
analyzer”.26 Network analyzer was used to identify hub
proteins, carrying the highest closeness centrality (CC),
betweenness centrality (BC), and the node degree as key
topological parameters.27 Network robustness was measured as
an iterative resilience in terms of removal of nodes. KEGG
pathways were used to visualize pathways within the networks,
and unconnected nodes were removed.
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For integrated pathway analyses of gene/protein expression
and metabolomics data, we applied Integrated Molecular
Pathway Level Analysis (IMPaLA).28
■ RESULTS AND DISCUSSION
The development of diet-induced insulin resistance and
treatment thereof involves complex physiological processes.
To investigate molecular aspects of these perturbations in WAT
and liver, we fed mice either with a LFD or HFD to induce
overweight and insulin resistance. We further treated insulin-
resistant HFD-fed mice with the antidiabetic drug rosiglitazone
to achieve insulin-sensitizing and lipid-lowering effects. Basic
physiological parameters such as body weight, plasma glucose,
insulin, triglycerides, free fatty acids, and homeostatic model
assessment of insulin resistance (HOMA-IR) index confirmed
diet-induced obesity and insulin resistance, as well as
physiological effects of rosiglitazone drug treatment are
summarized in Table 1.
Regulation of Molecules on the Transcriptome, Proteome,
and Metabolome Level in White Adipose Tissue and Liver
Using microarray-based RNA expression analysis, we detected
about 10 000 expressed genes in WAT and liver tissues.
Strikingly regulated transcripts between LFD, HFD, and RGZ
treatment are indicated in Figure 1A for WAT and Figure 1B
for liver tissue. These transcripts can be attributed to various
cellular functions such as inflammation or fatty acid
metabolism.
More background information on the biological context of
the most interesting regulated transcripts is provided in the
Supporting Information. The highlighted gene transcripts may
serve as a starting point for further mechanistic analysis and
potentially represent candidates for biomarker development.
For further holistic analysis, we considered the full data set
displayed in Figure 1 to extract biological pathway information
(see below).
In the proteomics data sets, we then identified several
thousand proteins of which one-quarter was ≥2-fold regulated
in LFD versus HFD and only a fraction of 7% upon RZG
treatment in WAT as well as liver tissue. As for the
transcriptome data, we analogously analyzed protein expression
changes in white adipose and liver tissue, and we identified
strongly up and down regulated proteins resulting from the
diseased HFD-state or intervention by RGZ-treatment (Figure
2). Notably, many of the highly regulated proteins could not be
observed in the transcriptomics analysis, with few exceptions,
suggesting differential regulation and life times of RNAs and
proteins.
As shown in Figure 2A, the entire set of identified proteins
showed higher alterations compared to the RNA expression
data set in WAT. Up regulated proteins in HFD compared to
the LFD condition were histone proteins such as HIST1H1A,
HIST1H1B, and FBN1, a structural component of extracellular
microfibrils. The most striking down regulated proteins in HFD
compared to the LFD condition were the following: fatty acid
binding protein 1 (FABP1); proteins involved in mitochondrial
context such as HSD17B10, PHB, UQCRC1, ADH1, and TST;
and also ACTA2 (alpha-actin 2), a protein rather known in the
context of muscle, which may probably also be involved in the
context of cell motility, structure, and integrity of adipocytes.
Cytoskeleton rearrangements have been found previously in
this context.29 Proteins which were down regulated in HFD and
up regulated by RGZ treatment were actin-binding proteins
TAGLN and TAGLN2; EPHX2, involved in xenobiotic
Table 1. Analyzed Physiological Parameters of LFD-Fed,
HFD-Fed, and RGZ-Treated HFD-Fed Mice
parameter LFD HFD HFD + RGZ
body weight (g) 28.1 ± 1.5 41.7 ± 2.3 42.5 ± 4.4
plasma glucose (mM) 4.8 ± 1.0 7.2 ± 1.3 6.3 ± 1.0
plasma insulin (ng/mL) 0.7 ± 0.2 1.3 ± 0.3 0.8 ± 0.4
HOMA-IR 3.5 ± 0.9 10.9 ± 3.0 5.7 ± 3.9
plasma triglycerides (mM) 0.6 ± 0.1 1.8 ± 0.3 1.3 ± 0.2
plasma free fatty acids (mM) 0.4 ± 0.2 0.5 ± 0.1 0.3 ± 0.1
Figure 1. Log−log plot of the two conditions LFD/HFD and RGZ-HFD/HFD based on RNA expression ratios. (A) WAT, (B) liver tissue. The
entire set of identified RNAs was distributed around the “unregulated” center. Strong gene expression changes are indicated, and biological
background information is provided in the Supporting Information.
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metabolism of drugs; and ACACB, which may play a role in the
regulation of fatty acid oxidation. Proteins that were down
regulated in HFD and counteractively up regulated due to RGZ
treatment were HP, haptoglobin, known to be involved in
heme iron metabolism and also in the acute phase response,
depending on the physiological context; proteins involved in
cellular structure such as TUBA8, NUP153 and SERPHINH1;
and proteins involved in protein degradation such as RAD23B
and SUMO2. Detailed information on the biological context of
the highest regulated proteins in liver is given in the Supporting
Information.
Finally, applying state-of-the-art targeted LC-MS/MS based
metabolomics, we identified a set of 153 metabolites in WAT
and 142 in liver tissue (Figure 3A,B, Supporting Information,
Table 2). The entire set of identified metabolites was not at all
distributed around the “unregulated” center like the tran-
scriptome or proteome data. The metabolite data instead
showed high variance and fold changes.
In WAT, coenzyme A (CoA), important for the metabolism
of fatty acids and the oxidation of pyruvate in the citric acid
cycle, was 3.7-fold down regulated in the HFD compared to the
LFD state. Upon RGZ treatment, CoA amounts were even 2-
fold higher than LFD levels, potentially re-establishing energy
metabolism. Citicoline has been shown to restore the activity of
mitochondrial ATPase and membrane Na+/K+ ATPase and
has a neuroprotective effect in hypoxic and ischemic
conditions.30 Only in RGZ-treated WAT were we able to
detect a 7.5-fold up regulation of citicoline, whereas this
metabolite was unaffected in HFD versus LFD. This effect of
RGZ could potentially contribute to restore the significantly
deteriorated OXPHOS system in the HFD state, which was
Figure 2. Log−log plot of the two conditions LFD/HFD and RGZ-HFD/HFD based on protein expression ratios. (A) WAT, (B) liver tissue.
Outstanding protein expression changes are indicated according to their gene names. Biological background information for liver proteins is provided
in the Supporting Information.
Figure 3. Log−log plot of the two conditions LFD/HFD and RGZ-HFD/HFD based on metabolite expression ratios. (A) WAT, (B) liver tissue.
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corroborated by protein expression data showing increased
expression of proteins involved in OXPHOS.
In liver, HFD compared to LFD state showed significant
changes in metabolite levels. In contrast, RGZ treatment only
showed marginal effects with few exceptions: The most
interesting regulated metabolites in liver were the sphingolipids
sphingosine (Sph) and sphingosine-1-phosphate (S1P). Sph
usually inhibits proliferation and promotes apoptosis, while S1P
stimulates tumor growth and suppresses apoptosis.31 These
metabolites are interconvertible; it is therefore believed that
their relative ratio determines cell fate. As shown in Figure 3B,
in liver tissue, the HFD/LFD ratio of Sph/S1P was 1:1.
Strikingly, upon RGZ treatment, nearly 100% of S1P was
converted to Sph, shifting the organ to a pro-apoptotic state,
indicating potential hepatic toxicity of some thiazolidinediones,
as recently reported.32
Another major regulated metabolite was N-acetylneuraminic
acid (NANA, also known as sialic acid), which was increased in
type 2 diabetes mellitus.33 NANA levels were unchanged when
HFD and LFD states were compared, but they decreased 12-
fold upon RGZ treatment of HFD mice, confirming the insulin-
sensitizing effects of RGZ.
In liver, allantoin was 20-fold elevated in the HFD state.
However, in contrast to WAT, RGZ treatment could restore
normal levels of allantoin, indicating metabolically beneficial
effects.
All measured vitamin B metabolites (B1, B2, B5, B6, and
biotin) were highly reduced in the HFD liver (6-fold in
average) compared to LFD, and RGZ treatment could not
restore these reduced metabolite levels (Figure 3B). This was
consistent with the protein expression data, including strong
down regulation of proteins involved in vitamin B metabolism
(B6, folic acid), namely, PDXDC1 and DHFR. Furthermore,
the dipeptide cystathionine was down regulated in HFD liver.
Notably, excess levels of cystathionine in urine are an indicator
of a prominent manifestation of vitamin-B6 deficiency called
cystathioninuria.34 Further research has to be done to elucidate
the role of cystathionine in the context of liver and diabetes.
The biological roles of further metabolites, which are not
mentioned here, are described in Supporting Information.
Figure 4. Acylcarnitines are presented according to their molecular
masses on the X-axis against their log10 ratios of LFD/HFD and RGZ-
HFD/HFD conditions in (A) WAT and (B) liver tissue. SD of MRMs,
linear regression lines, and according p values are indicated.
Figure 5. Network of down regulated proteins in (A) LFD/HFD and (B) RGZ-HFD/HFD fat tissue, visualized by STRING software (version 9.1).
The top hub proteins are indicated according to Table 2. Proteins are colored according their KEGG pathway affiliation: red = BCAA, yellow = TCA
cycle, and green = OXPHOS.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr5005828 | J. Proteome Res. XXXX, XXX, XXX−XXXF
Acylcarnitines: An Interesting Example of the Metabolite
Data Sets
Carnitine and its acyl esters, the acylcarnitines, are essential
compounds for the metabolism of fatty acids. As the acylation
state of carnitine in the plasma reflects the composition of the
cytosolic acylcarnitine pool, this serves as a diagnostic marker
for the equilibrium between acyl-CoA and acylcarnitine species.
For example, acylcarnitines generated as products of incom-
plete mitochondrial fatty acid oxidation have been detected in
obesity, type 2 diabetes, cardiovascular disease, and encephal-
opathy and frequently lead to low levels of acetyl-CoA and
dysfunction of the citric acid cycle.35 Although most studies
analyzed acylcarnitines in plasma, we focused on tissues.
Short acylcarnitines were down regulated in WAT-HFD
state, whereas long acylcarnitines were up regulated, compared
to both LFD and RGZ treatment (Figure 4A, Supporting
Information, Table 3A). In liver, we observed similar regulation
patterns for LFD versus HFD. However, for the RGZ
treatment, we discovered an antiparallel regulation (Figure
4B, Supporting Information, Table 3B). Carnitine levels and
short acylcarnitines were down regulated, but longer
acylcarnitines were up regulated compared to HFD, suggesting
a significant influence of RGZ on the fatty acid metabolism as
energy source.
Others have found that short and long acylcarnitines can be
differentially regulated in diabetes derived from plasma
samples.36−38 The reason remains speculative; however, it has
been suggested that inefficient beta-oxidation of long-chain
fatty acids, in part due to a relatively low citric acid cycle
capacity, increases tissue accumulation of acetyl-CoA, which in
turn generates chain-shortened acylcarnitines that trigger
proinflammatory pathways involved in insulin resistance.36
Our data seem to corroborate this hypothesis.
Holistic Views on Gene and Protein Expression and on
Metabolomics Data
This is one of the first studies, which provides combined
comprehensive “omics” data on three biological levels in a
disease-relevant in vivo context. Figures 1−3 show that most of
the transcripts were indeed unregulated, whereas the
metabolome displayed a strong regulation. If we put these
“optic impressions” into numbers (e.g., for LFD versus HFD
liver), we find that the transcriptome ratios showed the smallest
Table 2. Network Analysis of down Regulated LFD/HFD and RGZ-HFD/HFD Proteins in WAT To Determine the Main Hubs
in Terms of Robustness and Betweenness Centrality




SDHB 164 4.66 12 20 0.21 0.34
SUCLG1 163 4.81 12 21 0.12 0.34
NDUFS1 158 6.82 19 16 0.11 0.32
EHHADH 154 7.48 21 18 0.08 0.27
ACAA2 152 7.87 21 18 0.05 0.32




SUCLG1 107 2.98 8 21 0.27 0.52
UQCRC1 106 3.10 8 27 0.16 0.50
NDUFB5 105 3.38 9 23 0.06 0.48
SDHB 104 3.52 9 16 0.04 0.43
DLAT 102 4.05 11 12 0.05 0.38
HADHB 100 4.46 11 19 0.12 0.45
Nodes are connected proteins within a network; the average distance between nodes is calculated after removal of a node; the diameter of a network
is defined as the longest of all calculated shortest paths in a network. All these three criteria are indicators of the network robustness and resilience.
Node degree is the number of connections between one node to others; the betweenness centrality is equal to the number of shortest paths from all
vertices to all others that pass through that node; closeness centrality is the distance metric between all nodes, defined by the length of their shortest
paths.
Figure 6. Visualization of selected significantly regulated KEGG
pathways of RNA, protein, and metabolite data based on the pathway
overrepresentation analysis. (A) WAT, (B) liver tissue.
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standard deviation of 0.122, the proteome had the next largest
at 0.329, and the metabolome had the largest standard
deviation of 0.535all of which were based on log10 fold
ratios. Comparing the expression levels of individual RNAs with
their corresponding proteins, the mean correlation coefficient
was 65% from all analyzed tissues and treatments (Supporting
Information, Figure 1A,C), suggesting rather slight correlation
between gene and corresponding protein expression. However,
regulation on the pathway level showed a higher mean
correlation coefficient of 73% over all analyzed tissues and
treatments (Supporting Information, Figure 1B,D).
Varying or even contradicting data correlations between
transcriptome and proteome have already been observed by
different research groups.39,40 Weak data correlation can be
explained in part by molecular events such as alternative
splicing, assembly into complexes, post transcriptional mod-
ifications, secretion, and different half-life times of RNAs and
proteins, among others. In general, our analyses indicated
improved correlation of genes and proteins on the pathway
level, indicating that physiological plasticity to counteract
chronic metabolic stress in peripheral tissues such as WAT and
liver may result from the concerted action of gene and protein
ensembles, rather than from the isolated action of single
players.
Network Analysis
Using our protein expression data sets, we analyzed protein
networks to infer and characterize hub proteins that may exert
major functions during HFD and drug treatment with RGZ.
Only the proteins which were down regulated in LFD/HFD
and RGZ-HFD/HFD in WAT generated large networks
(Figure 5), in contrast to liver tissue. The KEGG pathway
affiliation of these networks was examined and revealed that the
networks belong to energy metabolism (e.g., OXPHOS, TCA
cycle, and branched chain amino acids (BCAA)). The network
similarity between LFD/HFD and RGZ-HFD/HFD in WAT
(Figure 5) shows that the drug treatment by RGZ puts the
HFD condition in part back to a LFD-like condition. This was
confirmed by a direct network comparison of LFD versus RGZ-
HFD, resulting in a neutralization of the TCA and OXPHOS
networks (Supporting Information, Figure 2).
To identify the main important proteins within the discussed
networks, we used the Cytoscape plug in “network analyzer”
and a robustness test to identify the hubs. The main hub
protein (in terms of centrality and robustness) in both
networks was succinate dehydrogenase iron−sulfur subunit
(SDHB; 2-fold up regulated due to HFD, 1.5-fold up regulated
due to RGZ treatment), part of the TCA cycle and respiratory
chain. Furthermore, succinyl-CoA ligase subunit alpha
(SUCLG1; 1.5 fold up regulated for HFD and for RGZ),
catalyzing the ATP- or GTP-dependent ligation of succinate
and CoA to form succinyl-CoA was a main hub (Table 2). This
shows again the effectiveness of RGZ to turn HFD WAT into a
LFD-like condition.
Integrating Transcriptomics, Proteomics, and
Metabolomics Data
As discussed above, a number of genes, proteins, and
metabolites were detected, which deserve further attention
and in depth functional study and validation as potential
biomarkers. On the other hand, it seems that the biological
function of complex physiological processes in diet-induced
insulin resistance and during drug treatment might be more
adequately described on the pathways level rather than focusing
Figure 7. Simplified TCA cycle featuring transcriptomics, proteomics, and metabolomics regulations of LFD versus HFD in white adipose tissue,
according to KEGG nomenclature. Transcriptomics data are presented as ovals, proteomics data as rectangles, metabolites by name. Regulation is
color coded in which red stands for up regulated, blue for down regulated, and black for unregulated. For transcriptomics and proteomics, ≥ 1.5-fold
changes were regarded as regulated, and for metabolomics, ≥ 2-fold changes were regarded as regulated.
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excessively on individual molecules, thereby potentially loosing
causative context.2,3
Clearly, as a result of current technical maturity and
feasibility, RNA expression data are presently the most
comprehensive and the most informative and include more
than 10 000 detected genes, followed by the proteomics data
sets with about 3500 detected proteins, and metabolites data
sets containing few hundreds of molecules.
In order to combine and strengthen pathway analyses of
these data sets, we applied integrated pathway enrichment
analysis (IMPaLa),28 as shown in Figure 6. Significant pathways
and their log10 FDR values from all three omics data sets were
integrated. As a result of HFD, mitochondrial energy
metabolism and BCAA metabolism were the most significant
deregulated pathways in WAT. Upon RGZ treatment, the
PPAR signaling pathway was identified as deregulated,
indicating a distinct effect of the PPARγ-targeting drug RGZ
in WAT (Figure 6A). In liver (Figure 6B), we observed that
oxidative phosphorylation and ribosomes were the most
deregulated pathways in HFD mice. Notably, our integrated
pathway analysis revealed that RGZ treatment did not show
strong regulation in liver, consistent with the rather low
abundance of PPARγ in this tissue. This analysis indicated high
specificity of RGZ for PPARγ compared to PPARα, which is
highly abundant in liver, or the ubiquitously expressed PPARβ/
δ.
For a more detailed pathway analysis of transcripts, proteins,
and metabolites, we picked the citric acid cycle (TCA) as a
strongly regulated pathway between HFD/LFD condition in
WAT (Figure 7). More than half of the detected RNAs were at
least 1.5-fold up regulated, whereas all detected proteins in this
pathway were not significantly regulated on the basis of
individual protein ratios, although the whole protein pathway
was significantly up regulated (see Supporting Information,
Figure 1B). Notably, although RNA and protein levels were up
regulated, metabolites within the TCA cycle were down
regulated, except incoming acetyl-CoA, which was 2-fold up
regulated. This result shows fine-tuned regulations at the three
investigated interconnected biological levels: Up regulated
levels of RNAs or proteins do not necessarily mean that there
are more metabolites present, but may rather indicate
compensatory relative effects to regain metabolic homeostasis.
We further analyzed the valine, leucine, and isoleucine
degradation pathway in more detail between LFD/HFD
condition in WAT (Figure 8).
We observed a significant up regulation on the BCAA
pathway level for RNA and protein data sets (Supporting
Information, Figure 1B). Notably, a recent study of morbidly
obese subjects with type 2 diabetes suggested that the reduction
in blood of BCAA resulting from gastric bypass surgery may be
associated with improvement in blood sugar regulation.41 Our
data indicate that increased amounts of BCAA induce an
increasing expression of genes and proteins required for
degradation of BCAA. Furthermore, the up regulation of this
pathway could be a compensatory reaction for the down
regulated energy metabolism in the HFD state, as this amino
acid breakdown generates acyl-CoA derivatives, which can enter
the TCA cycle.
■ CONCLUSIONS AND OUTLOOK
To the best of our knowledge, this is one of the first studies
integrating transcriptomics, proteomics, and metabolomics data
sets to analyze in mammalian tissues disease states and medical
intervention in a preclinical setting.
Many diabetes-indicative plasma biomarkers such as BCAAs
and acylcarnitines could be found in this study in the context of
WAT and liver, corroborating recent findings that were
exclusively based on analyzing plasma.11,12,42 As described
above, we further detected a number of RNA-, protein-, and
metabolite-based biomarker candidates. In particular, we
observed up regulation of HFD responsive proteins of TCA
cycle and OXPHOS such as SDHB and SUCLG1 in WAT and
down regulation of HFD responsive proteins involved in
vitamin B metabolism such as PDXDC1 and DHFR in liver.
Consistently, we detected down regulation of metabolites from
the vitamin B group. Moreover, we found the sphingosine/
sphingosine 1-phosphate pair as a potential marker for
xenobiotic effects in liver. Using network and pathway analyses,
we could demonstrate in major pathways (TCA cycle,
OXPHOS, and BCAA metabolism) the adverse effects of
HFD and specific restoring effects of rosiglitazone treatment in
WAT. Identified proteins and metabolites need to be further
validated, either as single markers or as marker sets for targeted
and integrated genomics, proteomics, and metabolomics
approaches.
Figure 8. Simplified valine, leucine, and isoleucine degradation
pathway featuring transcriptomics, proteomics, and metabolomics
regulations of LFD versus HFD in white adipose tissue. Tran-
scriptomics data are presented as ovals, proteomics data as rectangles,
metabolites by name. Regulation is color coded in which red stands for
up regulated, blue for down regulated, and black for unregulated. For
transcriptomics and proteomics, ≥ 1.5-fold changes were regarded as
regulated, and for metabolomics, ≥ 2-fold changes were regarded as
regulated.
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